摘要
目的:探讨氨溴索注射液佐治新生儿呼吸窘迫综合征(ARDS)的疗效。方法:将确诊为ARDS的足月新生儿30例随机分为对照组和治疗组,两组均给予基础对症治疗,治疗组加用氨溴索注射液15mg静脉滴注,2次/d。比较两组呼吸窘迫缓解时间、并发症发生率及病死率。结果:呼吸窘迫缓解时间治疗组(4±1.0)d,对照组(7±1.5)d;发生并发症治疗组6例(37.5%),对照组9例(64.3%);病死患儿治疗组2例(12.5%),对照组5例(35.7%),两组呼吸窘迫缓解时间比较差异有统计学意义(P<0.05)。结论:氨溴索注射液佐治足月新生儿ARDS可缩短呼吸窘迫缓解时间,降低并发症发生率和病死率。
Objective： To study the effects of ambroxol as an adjuvant therapy in ARDS in full-term new bores. Methods： 30 full-term new bores with ARDS were divided into two groups randomly. Two groups were all treated with synthetical therapy but treatment group were treated with ambroxol （15 mg, iv, twice a day） in addition. Two groups were compared with catabafic time of respiratory distress, probability of complication and death rate. Results： The catabatic time of respiratory distress was （4 ± 1.0） days, 6 cases （37.5%） with complication, 2 cases （12.5%） were dead in treatment group; the catabatic time of respiratory distress is （7 ± 1.5） days, 9 cases （64.3%） with complication, 5 eases （35.7%） were dead in control group. The difference in comparison of the results between treatment group and control group was very distinct （P 〈 0.01 ）. Conclusions： Ambroxol can shorten the catabatic time of respiratory distress and reduce probability of complication and death rate as a adjuvant therapy for acute respiratory distress syndrome （ARDS） in full-term new bores.
出处
《儿科药学杂志》
CAS
2006年第2期32-33,共2页
Journal of Pediatric Pharmacy
关键词
氨溴索
新生儿
呼吸窘迫综合征
Ambroxol
New bores
Respiratory distress syndrome
